Trump Policies Trigger Pharma Shakeup: Expert Predicts Industry Consolidation

President Trump’s policies and executive orders have had a significant impact on the pharmaceutical industry, according to Dr. Scott Gottlieb, former FDA commissioner. In a recent CNBC interview, Gottlieb detailed how tariffs on drugs manufactured in Ireland and the Inflation Reduction Act's price controls are affecting pharmaceutical companies' bottom lines. "If they put a 10 or 20% tariff on those drugs, that's going to hit the bottom line of a lot of drug companies," Gottlieb stated. He predicts this will lead to industry consolidation and a shift of R&D to China. The analysis underscores the complex relationship between government policy, global economics, and the pharmaceutical sector.